<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Evan Albright — Digest tagged &quot;nhs&quot;</title><description>Digest issues tagged #nhs.</description><link>https://www.evanalbright.com/</link><language>en-us</language><item><title>FDA loses two leaders in one week as Ebola outbreak draws WHO emergency declaration</title><link>https://www.evanalbright.com/digest/2026-05-17/</link><guid isPermaLink="true">https://www.evanalbright.com/digest/2026-05-17/</guid><description>The FDA&apos;s leadership vacuum deepened this week as the drug center head followed Commissioner Makary out the door, leaving the agency with no confirmed leadership at its two most critical posts. Open-weight models kept multiplying with Gemma 4, DeepSeek V4, and Kimi K2.6 all dropping in the same month, while Sebastian Raschka&apos;s analysis of new KV-sharing and compressed attention techniques explains why long-context costs are falling fast. A rare Bundibugyo Ebola outbreak in Congo&apos;s Ituri province prompted a WHO public health emergency declaration, and the WHO&apos;s move landed as hantavirus conspiracy theories were already cycling through social media. On the economy side, Trump&apos;s China visit produced mixed signals on decoupling, while Noah Smith argued that Europe&apos;s comfortable stagnation is no longer viable.</description><pubDate>Sun, 17 May 2026 00:00:00 GMT</pubDate><category>ai</category><category>software</category><category>pharma</category><category>healthtech</category><category>economy</category><category>fda</category><category>llm</category><category>open-source</category><category>ebola</category><category>trade</category><category>attention</category><category>inference</category><category>efficiency</category><category>evals</category><category>china</category><category>benchmarks</category><category>ecosystem</category><category>strategy</category><category>rl</category><category>self-play</category><category>reasoning</category><category>alphago</category><category>rlvr</category><category>science</category><category>research</category><category>scaling</category><category>ai-safety</category><category>forecasting</category><category>products</category><category>startups</category><category>productivity</category><category>operations</category><category>processes</category><category>pricing</category><category>enterprise</category><category>saas</category><category>gpt</category><category>agents</category><category>chatgpt</category><category>fintech</category><category>openai</category><category>product</category><category>policy</category><category>government</category><category>local-llm</category><category>apple-silicon</category><category>cost</category><category>pretraining</category><category>infrastructure</category><category>training</category><category>nvidia</category><category>models</category><category>deepseek</category><category>competition</category><category>anthropic</category><category>claude</category><category>design</category><category>tools</category><category>jobs</category><category>layoffs</category><category>industry</category><category>data</category><category>transformers</category><category>architecture</category><category>limitations</category><category>safety</category><category>datasette</category><category>plugins</category><category>cost-control</category><category>security</category><category>windows</category><category>cryptography</category><category>exploit</category><category>supply-chain</category><category>npm</category><category>macos</category><category>css</category><category>frontend</category><category>engineering</category><category>clickhouse</category><category>performance</category><category>databases</category><category>nhs</category><category>leadership</category><category>regulation</category><category>cder</category><category>opinion</category><category>who</category><category>outbreak</category><category>pheic</category><category>m&amp;a</category><category>biopharma</category><category>dealmaking</category><category>gene-therapy</category><category>rare-disease</category><category>nonprofit</category><category>marketplace</category><category>senate</category><category>health-policy</category><category>screening</category><category>mammography</category><category>evidence</category><category>guidelines</category><category>hantavirus</category><category>public-health</category><category>risk</category><category>takeda</category><category>compliance</category><category>settlement</category><category>ma</category><category>consolidation</category><category>340b</category><category>amgen</category><category>prostate</category><category>oncology</category><category>biotech</category><category>misinformation</category><category>virology</category><category>epidemiology</category><category>cancer</category><category>mifepristone</category><category>supreme-court</category><category>abortion</category><category>access</category><category>clinical-trials</category><category>early-detection</category><category>tariffs</category><category>geopolitics</category><category>decoupling</category><category>europe</category><category>gdp</category><category>inequality</category><category>growth</category><category>prediction-markets</category><category>finance</category><category>investor-relations</category><category>capital-markets</category><category>private-equity</category></item></channel></rss>